Funding for this research was provided by:
National Institutes of Health (R21ES022153, 5U19AI057229, R01HL118612, S10RR027582)
Sean N. Parker Center for Allergy and Asthma Research, Stanford University
Received: 10 October 2020
Accepted: 8 January 2021
First Online: 18 January 2021
Ethics approval and consent to participate
: We used a Stanford IRB approved protocol to collect all the samples and perform the studies in a deidentified fashion as per CFR/GCP (code of federal regulation/good clinical practice) guidelines.
: Not applicable.
: Dr. Nadeau reports grants from National Institute of Allergy and Infectious Diseases (NIAID), Food Allergy Research & Education (FARE), End Allergies Together (EAT), Allergenis, and Ukko Pharma; Grant awardee at NIAID, National Institute of Environmental Health Sciences (NIEHS), National Heart, Lung, and Blood Institute (NHLBI), and the Environmental Protection Agency (EPA); is involved in Clinical trials with Regeneron, Genentech, AImmune Therapeutics, DBV Technologies, AnaptysBio, Adare Pharmaceuticals, and Stallergenes-Greer; Research Sponsorship by Novartis, Sanofi, Astellas, Nestle; Data and Safety Monitoring Board member at Novartis and NHLBI; Cofounded Before Brands, Alladapt, ForTra, and Iggenix; Chief Intellectual Office at FARE, Director of the World Allergy Organization (WAO) Center of Excellence at Stanford, Personal fees from Regeneron, Astrazeneca, ImmuneWorks, and Cour Pharmaceuticals; Consultant and Advisory Board Member at European Academy of Allergy and Clinical Immunology (EAACI) Research and Outreach Committee, Ukko, Before Brands, Alladapt, IgGenix, Probio, Vedanta, Centecor, Seed, Novartis, NHBLI, EPA, National Scientific Committee of Immune Tolerance Network (ITN) and NIH Programs; US patents for basophil test, multifood immunotherapy and prevention, monoclonal antibody from plasmablasts, and a device for diagnostics. The remaining authors declare no relevant competing interests.